Biomarker for Rapid Diagnosis of Hemispheric Stroke

Johann Wolfgang Goethe University Hospital250 enrolled

Overview

The aim of the study is to estimate the diagnostic accuracy of a combined biomarker test (including NMDA-Receptor fragments \[NR2-peptide\] and Glial fibrillary acidic protein) used to differentiate between cerebral ischemia and intracerebral hemorrhage in patients with acute hemispheric stroke.

Study Type

OBSERVATIONAL

Enrollment

250

Conditions

Acute Stroke

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * hemiparesis * at least one sign of cortical involvement (e.g., aphasia, neglect, gaze deviation, reduced level of consciousness) * hospital admission within 4.5 hours after symptom onset Exclusion Criteria: * stroke/TIA within the last 3 months * traumatic brain injury within the last 3 months * history of brain tumor

Locations (1)

Department of Neurology, Goethe-University

Frankfurt am Main, Germany

Outcomes

Primary Outcomes

Diagnostic accuracy (sensitivity and specificity for diagnosing cerebral ischemia and intracerebral hemorrhage)

Time frame: 9 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.